What is BRTX's market cap?

$2.09M, based on the Nov 5 close of $1.51.

Does BioRestorative Therapies, Inc. Common Stock (NV) pay a dividend?

No regular cash dividend has been paid in the last year.

How much of BRTX is sold short?

14.8K shares, 1.1% of float, as of Oct 15, 2026.

What sector is BRTX in?

Healthcare, in the Health Services industry.

NASDAQ · BRTXHealthcareHealth Services

BioRestorative Therapies, Inc. Common Stock (NV) (BRTX)

$1.510.00%

Close Nov 5, 2026 · split-adjusted

Oct 30, 2026$1.40▼ 95.33% in range

Nov 3, 2025Low $1.36 · High $59.20Oct 30, 2026

What changed · written from our data

As of Nov 5, 2026

BioRestorative Therapies, Inc. Common Stock (NV) closed at $1.51 on Nov 5, unchanged, 97.4% below its 52-week closing high. Volume of 20.5K shares was 0.59× its 20-day average (below normal).

Split-adjusted performance: -32.6% over one month, -66.4% over six months, -94.8% over one year.

In the quarter ended Mar 31, 2026, revenue was $23.17K, down 7.3% from a year earlier, with a net margin of -9298.3%.

Short interest was 14.8K shares at the Oct 15 settlement, up 12.4% from the prior report (1.1% of float, 1.0 days to cover).

Market cap$2.1M1.4M shares

Revenue · quarter$23.2K−7.3% YoY

Diluted EPS$-2.40—

P/E · TTM—P/S 5.8×

Net margin-9,298.3%Gross 68.1%

Dividend yieldNone

52-week range1.36 – 59.20−97.4% from high

Volume20.5K0.59× 20-day avg

Volatility · 60d886.5%Annualised

Short % of float1.1%1.0 days to cover

Net cash$3.6MCash $3.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −4.4%1M −32.6%3M −63.0%6M −66.4%YTD −93.6%1Y −94.8%3Y −96.2%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Health Services

Percentile among 20 companies (100 = best)

6-month momentum0

Revenue growth18

Net margin0

Value (low P/E)—

Size5

Industry medians: 6-month return +11.1%, revenue growth +7.2%, net margin 3.0%, P/E 72.1×.

Short interest

Details →

Shares short14.8K+12.4% vs prior

Days to cover1.0Settled Oct 15

% of float1.1%

Short vol. 10d25.8%of daily volume

Closest peers by size in Health Services

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
BRTXBioRestorative Therapies, Inc. Common Stock (NV)	$1.51	0.00%	−66.4%	−7.3%	−9298.3%	—	$2.1M
ATPCAgape ATP	$1.29	−13.42%	−51.5%	−93.4%	1117.4%	—	$1.3M	Compare
MGRXMangoceuticals	$0.1918	−7.39%	−43.6%	−37.9%	−5447.9%	—	$4.3M	Compare
PIIIP3 Health Partners	$3.82	−6.83%	+6.7%	+8.6%	−0.6%	—	$14.9M	Compare
DCGODocGo	$0.2436	−6.52%	−61.6%	−8.7%	−21.5%	—	$24.1M	Compare
CCELCryo-Cell International	$4.95	−2.37%	+38.3%	0.0%	16.2%	—	$39.9M	Compare
EUDAEUDA Health Holdings Limited	$14.82	−7.38%	+10.3%	—	—	—	$44.4M	Compare
PARKPark Dental Partners	$20.14	−5.65%	+19.3%	—	2.0%	—	$95.8M	Compare
VMDViemed Healthcare	$9.01	−10.88%	−2.2%	+23.9%	3.5%	23.7	$343.2M	Compare

News about BioRestorative Therapies, Inc. Common Stock (NV)

All news →

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline DataGlobeNewswire Inc. · May 26, 2026▲ Positive BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticalsGlobeNewswire Inc. · May 13, 2026▲ Positive BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026GlobeNewswire Inc. · Mar 5, 2026▲ Positive BioRestorative Announces Closing of $5.0 Million Public OfferingGlobeNewswire Inc. · Feb 14, 2026Neutral BioRestorative Announces Pricing of $5.0 Million Public OfferingGlobeNewswire Inc. · Feb 12, 2026Neutral

Quick answers

What does BioRestorative Therapies, Inc. Common Stock (NV) do?: BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain.
What is BRTX's market cap?: $2.09M, based on the Nov 5 close of $1.51.
Does BioRestorative Therapies, Inc. Common Stock (NV) pay a dividend?: No regular cash dividend has been paid in the last year.
How much of BRTX is sold short?: 14.8K shares, 1.1% of float, as of Oct 15, 2026.
What sector is BRTX in?: Healthcare, in the Health Services industry.

About BioRestorative Therapies, Inc. Common Stock (NV)

BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.

HQ: Melville, NY14 employeesListed Dec 22, 1997biorestorative.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology